Dr. Lacko has contributed to approved patents with leading US investigators at MD Anderson Cancer Center and at the NIH. His current interests include the establishment of a private venture to allow the clinical utilization and commercialization of their latest technology in therapeutic drug delivery.
- Shahzad MMK et al. Targeted delivery of small interfering RNA using reconstituted high-density lipoprotein nanoparticles, Neoplasia 2011;13(4):309-19. doi: 10.1593/neo.101372.
- Raut S. et al. Probing the Assembly of HDL Mimetic, Drug Carrying Nanoparticles Using Intrinsic Fluorescence. J Pharmacol Exp Ther. 2020; 373(1):113-121. PMID: 31941718.
- Sabnis N. etal. A Spontaneous Assembling Lipopeptide Nanoconjugate Transporting the Anthracycline Drug N-Benzyladriamycin-14-valerate for Personalized Therapy of Ewing Sarcoma. Bioconjug Chem. 2024; 35(2):187-202. doi:10.1021/acs.bioconjchem. 3c00429.